Related Experiment Video
Updated: May 29, 2026
07:54
Use of a Hanging-weight System for Isolated Renal Artery Occlusion
Published on: July 19, 2011
A TLR5 agonist inhibits acute renal ischemic failure
Nobuyuki Fukuzawa1, Marianne Petro, William M Baldwin
1Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Journal of Immunology (Baltimore, Md. : 1950)
|September 6, 2011
Summary
TLR5 agonist CBLB502 protects against acute kidney injury by reducing inflammation and tissue damage. Administration before or shortly after reperfusion mitigates renal failure, highlighting a therapeutic window.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Reperfusion of ischemic organs triggers inflammation via reactive oxygen species (ROS), leading to tissue damage.
- Radiation-induced injury, also ROS-mediated, is reduced by CBLB502, a TLR5 agonist derivative.
Purpose of the Study:
- To evaluate CBLB502's efficacy in mitigating acute ischemic renal failure in a murine model.
- To determine the therapeutic window for CBLB502 administration post-reperfusion.
Main Methods:
- Administered CBLB502 pre-occlusion and post-reperfusion in a murine model of bilateral renal pedicle occlusion.
- Assessed renal dysfunction, inflammation (leukocyte infiltration, cytokine production), and tubular injury.
- Utilized bone marrow chimeras to investigate MyD88 signaling in renal parenchymal cells.
Main Results:
- CBLB502 pretreatment significantly protected against renal dysfunction and inflammation.
- Post-reperfusion CBLB502 administration also showed protective effects, establishing a therapeutic window.
- Protection was mediated by MyD88 signaling in renal parenchymal cells expressing TLR5.
Conclusions:
- TLR5 agonists, like CBLB502, can mitigate and protect against acute renal ischemic failure.
- CBLB502 demonstrates potential as a therapeutic agent for ischemic kidney injury.
Related Concept Videos
01:22Acute Kidney Injury I: Introduction
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
01:29Acute Kidney Injury II: Pathophysiology
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...